CML - Chronic myeloid leukemia
GPX3 promoter methylation in chronic myeloid leukemia (CML) remains unknown. Our
... Chronic myeloid leukemia (CML) is a clonal dis- order of the leukemic stem cells characterized by excessive proliferation of stem cells in hema- topoietic tissues ...of CML is the ...
8
Appearance and Disappearance of Chronic Myeloid Leukemia (CML) in Patient with Chronic Lymphocytic Leukemia (CLL).
... lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML) are the most common leukemias of the elderly (>43 ...of CML followed by CLL in the same patient is extremely ...
5
Understanding cell signaling in cancer stem cells for targeted therapy – can phosphoproteomics help to reveal the secrets?
... CLL: Chronic lymphatic leukemia; CML: Chronic myeloid leukemia; CRPC: Castration-resistant prostate cancer; CSC: Cancer stem cells; CXCR4: G protein-coupled receptor chemokine ...
16
Memory T cells skew toward terminal differentiation in the CD8+ T cell population in patients with acute myeloid leukemia
... Acute myeloid leukemia; BM: Bone marrow; CML: Chronic myeloid leukemia; CR: Complete remission; HSCT: Hematopoietic stem cell transplantation; PB: Peripheral blood; PBMCs: ...
5
Mutations of c-Cbl in myeloid malignancies
... myelogenous leukemia; aUPD: acquired uniparental disomy; c-Cbl: Casitas B-lineage Lymphoma; CML: chronic myeloid leukemia; CMML: chronic myelomonocytic leukaemia; CMP: common ...
8
Invasive fungal infection among hematopoietic stem cell transplantation patients with mechanical ventilation in the intensive care unit
... Lymphoid Leukemia; AML: Acute Myeloid Leukemia; APACHE II: Acute Physiology and Chronic Health Evaluation II; BMT: Bone Marrow Transplantation; CML: Chronic Myeloid ...
7
Landscape of gene fusions in epithelial cancers: seq and ye shall find
... lymphoblastic leukemia; AML: Acute myeloid leukemia; APL: Acute promyelocytic leukemia, cholangio cholangiocarcinoma; CML: Chronic myeloid leukemia; CRC: Colorectal ...
18
Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case report
... A CML patient with oral dose of 400 mg/day for nine months of Gleevec who has no hematological, cytogenetic and molecular response to drug was investigated for ABL gene ATP-binding domain mutations responsible for ...
5
Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
... lymphoblastic leukemia; AP: Accelerated phase; BC: Blast crisis; CHR: Complete hematologic response; CM: Compound mutation; CML: Chronic myeloid leukemia; CP: Chronic phase; DFS: ...
14
Regulation of mitochondrial functions by protein phosphorylation and dephosphorylation
... disease; CML: chronic myeloid leukemia; BCR: breakpoint cluster region; AML: acute promyelocytic leukemia; PKA: protein kinase A; AKAP121: a kinase anchor proteins 121; PTPD1: protein ...
15
Quality control, modeling, and visualization of CRISPR screens with MAGeCK VISPR
... acute myeloid leukemia; CDF: cumulative distribution function; CML: chronic myeloid leukemia; CRISPR: clustered regularly interspaced short palindromic repeats; D3: Data-Driven ...
13
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
... lymphoblastic leukemia; ATO: Arsenic trioxide; ATRA: All-trans retinoic acid; CDx: Companion diagnostics; CLL: Chronic lymphocytic leukemia; CML: Chronic myeloid leukemia; ...
10
Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
... from a phase III trial of newly diagnosed CML-CP within 3 months after the administration of 500 mg/day of bosu- tinib [8]. Although the initial standard dose was 500 mg/ day in this trial, dose reductions of ...
8
Individualizing kinase targeted cancer therapy: the paradigm of chronic myeloid leukemia
... T315I-mutant CML a prime indication for selec- tion of ponatinib ...of leukemia cells using short hairpin RNAs (shRNAs) that si- lence kinase sequences or kinase inhibitor library panels may uncover novel ...
11
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
... for CML, and of the five widely available TKIs, four—imatinib [14], nilotinib [15], dasatinib [16], and bosutinib [1]—are approved for 1L treatment of CML (Table ...with CML who have the T315I ...
12
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
... of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with multi-TKI-resistant disease, NGS showed that BCR- ABL1 KD mutation status may be much more ...
9
Targeted treatment of chronic myeloid leukemia: role of imatinib
... Abstract: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of pleuripotent hematopoetic stem ...of CML is 1 to 2 cases per 100,000 ...
10
Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
... of chronic myeloid leukemia (CML) has completely altered the landscape of this once life-threat- ening ...of CML, and the specifics of its clinical impact and pharmacologic distinctions ...
7
Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case report
... Progression from CP to AP and BP is associated with acquisition of additional chromosomal abnormalities (ACAs). ACAs of trisomy 8, isochromosome 17q, and Philadelphia chromosome amplification, often referred to as ...
6
Multiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11)
... chronic phase of chronic myeloid leukemia (CML), with 2.5% myeloblasts, 5.5% promyelocytes, 13% myelocytes, 13% metamyelocytes, 1.5% eosinophils and 9% basophils. A multiplex PCR screen ...
5